Tapotoclax

N/A

Report date: 2024/02/05 16:46:31
NME

Base Information

Drug NameTapotoclax
Drug Alias NameAMG-176
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInduced myeloid leukemia cell differentiation protein Mcl-1 inhibitors
TargetsInduced myeloid leukemia cell differentiation protein Mcl-1
Therapy Area/IndicationsMyelodysplastic SyndromesHematologic NeoplasmsMultiple Myeloma +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesAustralia +[6] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesBeOne Medicines Ltd
Inactive CompaniesAbbvie IncAmgen Inc
Active IndicationsHematologic Neoplasms
Inactive IndicationsMyelodysplastic SyndromesMultiple MyelomaLymphoma, Large B-Cell, Diffuse +[6] 

Other Information

ATC CodeN/A
Related LinksDrugBank